Validation of Alveolar Probe-based Confocal Laser Endomicroscopy Descriptors in Diffuse Parenchymal Lung Diseases

Diffuse Parenchymal Lung Diseases Clinical Trial

— Microsemio-PI  

Official title:

Validation of Alveolar Probe-based Confocal Laser Endomicroscopy Descriptors in Diffuse Parenchymal Lung Diseases : A Multicentric Prospective Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT02961335
• Other study ID #: 2014/208/HP
• Status: Not yet recruiting
• Phase: N/A
• Start date: September 2018
• Est. completion date: February 2021

Study information

• Verified date: May 2018
• Source: University Hospital, Rouen
• Contact: Luc THIBERVILLE, Pr
• Email: luc.thiverville[@]chu-rouen.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Diffuse parenchymal lung diseases (DPLD) include a variety of respiratory conditions that affect either the pulmonary interstitium or the alveolar space . The etiological diagnosis of DPLD is often challenging, because of the large number of pathological entities involved, which share close clinical and radiological presentations. High resolution Chest CT, a key diagnostic procedure in DPLD, is subject to significant inter-observer analysis variations, so that the diagnosis sometimes requires a surgical or transbronchial lung biopsy sampling. This invasive procedure is not devoid of morbidity and may be impossible to perform in fragile patients. Therefore, the definite diagnosis of DPLD is usually achieved following a multi-disciplinary expert consensus, based on careful medical history, chest CT and bronchoalveolar lavage examinations.

Alveolar probe-based confocal laser endomicroscopy (pCLE) is a mini invasive endoscopic technique that allows distal lung microscopic imaging in vivo, during a flexible bronchoscopy performed under topical anaesthesia. Since 2006, Alveolar pCLE has been used in a monocentric clinical trial at the Rouen University Hospital in more than 200 patients and healthy volunteers. This allowed the first pCLE in-vivo description of normal pulmonary acinus, and confirmed the safety of the technique.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 240
• Est. completion date: February 2021
• Est. primary completion date: February 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age = 18

• signed written informed consent

• indication for a flexible bronchoscopy

• DPLD characterized by clinical and radiological data compatible with : idiopathic pulmonary fibrosis (IPF), acute or chronic hypersensitivity pneumonitis (HPS), sarcoidosis, or asbestosis.

• Initial histological confirmation of the disease is not required for the inclusion of the patient and the realisation of the alveolar bronchoscopy.

• non-smoking or smoking cessation >6 month

• Patient affiliated with, or beneficiary of a social security category

Exclusion Criteria:

• respiratory failure and contraindication for a flexible bronchoscopy (this item will stay at the appreciation of the physician, arterial blood gaz sampling being not required)

• bleeding disorder which would be not compatible with the realization of a flexible bronchoscopy

• history of pneumonectomy or non functional lung controlateral to the pCLE procedure

• patients for which a per-endoscopic distal lung cryobiopsy is forecasted during the first diagnostic bronchoscopy,

• patients for which the bronchoscopy needs a general anesthesia and mechanical ventilation during the procedure

• anticoagulant or platelet aggregation inhibitors that cannot be interrupted for the flexible bronchoscopy

• patients for which a follow up or an adequate work-up to achieve the final diagnosis will not be possible.

• patients for which a cryobiopsy is forecasted during the bronchoscopy

• pregnant and breast feeding women, or women of childbearing potential not taking adequate contraception

• Patients unable to understand informed consent

• Patient on major legal measure of protection

• Patients participating in an other interventional clinical trial at the inclusion date

Related Conditions & MeSH terms

• Diffuse Parenchymal Lung Diseases
• Lung Diseases
• Lung Diseases, Interstitial

Intervention

Procedure:
• Bronchoscopy
Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done
• Confocal microendoscopy
Confocal microendoscopy will be performed during this initial bronchoscopy
• Biopsy sampling
Patient who need to undergo bronchoscopy. During bronchoscopy, biopsy sampling and Confocal microendoscopy will be done

Locations

Country	Name	City	State
France	Rouen University Hospital	Rouen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Rouen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Sensitivity of confocal imaging (solid pattern) for the diagnostic of the pulmonary nodule	Confocal imaging will be considered as "positive" when both; a solid pattern is displayed; a diagnostic biopsy is obtained at the site of confocal imaging	Day 1